GRI will release topline 12-week study data this week. All indications are that data will be positive. The price continues to test $2.2 resistance. This will be broken soon.While all price movements are relative and unique, other companies with failed IPF trials lost ~$300M in market cap upon announcement. Others with successful trails have gained billions. GRI is worth approximately $6M today. Lots of room for upward valuation.
Note
They've missed two self-imposed deadlines to release biomarker Phase2b topline data. The delays with no explanation is unacceptable. I still, however, expect the data to be positive in nature. If no data release or statement this week I will cut it loose.Trade closed manually
They released great data today, and also announced they are diluting shares by over 100% of outstanding shares, including even MORE shares in the form of warrants.GRI has no idea how to manage their stock value, or they don't care.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.